Xeris Biopharma Holdings outlined the clinical development roadmap for its thyroid treatment XP-8121, including a potential for peak revenues of $1 billion to $3 billion, while anticipating initiation of the Cornerstone study by year-end 2026.
Xeris Biopharma Holdings outlined the clinical development roadmap for its thyroid treatment XP-8121, including a potential for peak revenues of $1 billion to $3 billion, while anticipating initiation of the Cornerstone study by year-end 2026.